Bimatoprost
- Atc Codes:S01EE03
- CAS Codes:155206-00-1
- PHARMGKB ID:155206-00-1
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
Brand Names
Europe
Austria: Lumigan; Belgium: Lumigan; Bulgaria: Lumigan; Cyprus: Lumigan; Czech Republic: Lumigan; Denmark: Lumigan; Estonia: Lumigan; Finland: Lumigan; France: Lumigan; Germany: Lumigan; Greece: Lumigan; Hungary: Lumigan; Ireland: Lumigan; Italy: Lumigan; Latvia: Lumigan; Lithuania: Lumigan; Luxembourg: Lumigan; Malta: Lumigan; Netherlands: Lumigan; Poland: Lumigan; Portugal: Lumigan; Romania: Lumigan; Slovakia: Lumigan; Slovenia: Lumigan; Spain: Lumigán; Sweden: Lumigan; UK: Lumigan.
North America
Canada: Lumigan; USA: Lumigan.
Latin America
Argentina: Lumigán; Brazil: Lumigan; Mexico: Lumigán.
Drug combinations
Bimatoprost and Timolol
Chemistry
Bimatoprost: C~25~H~37~NO~4~. Mw: 415.57. (1) 5-Heptenamide, 7-[3,5-dihydroxy-2-(3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl]-N-ethyl-, [1R-1[α(Z),2β(1E,3S*)3α,5α]]-; (2)(Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-N-ethyl-5-heptenamide. CAS-155206-00-1 (2001).
Pharmacologic Category
Antiglaucoma Agents; Prostaglandin Analogs. (ATC-Code: S01EE03).
Mechanism of action
Bimatoprost, a prostamide, is a synthetic prostaglandin analog which is an ocular hypotensive agent. Mimics the effects of endogenous prostamides and exhibits little or no pharmacologic activity at prostanoid receptors. Reduces intraocular pressure (IOP) 7-8 mmHg by facilitating outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes.
Therapeutic use
Reduction of intraocular pressure in open-angle glaucoma or ocular hypertension.
Pregnancy and lactiation implications
Decreased gestation, decreased body weight, increased late resorptions, and increased mortality were observed in animal studies with oral doses achieving serum levels >33 times human exposure. There are no adequate and well-controlled studies in pregnant women. Use with caution during lactation.
Unlabeled use
Contraindications
Hypersensitivity to bimatoprost or any component of the formulation.
Warnings and precautions
Inadvertent contamination of multiple-dose ophthalmic solutions has caused bacterial keratitis. May cause permanent changes in color of eye (increases the amount of brown pigment in the iris), eyelid skin and eyelashes. May also increase the length and/or number of eyelashes (may vary between eyes). Therapy may be discontinued if increased pigmentation persists. Caution in patients with intraocular inflammation, aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with risk factors for macular edema. Contains benzalkonium chloride (may be adsorbed by contact lenses). May be used with other eye drops to lower intraocular pressure.